exemestane,tamoxifen,triptorelin
azurity pharmaceuticals,astrazeneca,pfizer
['ovarian', 'breast', 'tamoxi', 'exemestane', 'soft trial']
soft trial: in premenopausal breast cancer patients revealed that the addition of ovarian function suppression (ofs) to adjuvant endocrine therapy with either tamoxifen (t+ofs) or exemestane (e+ofs) reduces the risk of recurrence compared with adjuvant tamoxifen alone. #asco23